Pseudomonas aeruginosa is a rod shaped, gram negative, monoflagellated, aerobic to facultative anaerobe bacteria which commonly inhabits soil and aqueous environments.1,2 Pseudomonas Exotoxin A (PE) is the most potent virulence factor secreted by some strains of P. aeruginosa It is composed of three structural domains, N-terminal domain (I) responsible for the toxin binding to its host cell receptor, middle domain (II) has a role in toxin translocation across the membrane, and C-terminal domain (III) which has ADP-ribosylation activity.4,5
Synonyms: PE; ETA; Pseudomonas Exotoxin A
Storage: -20C
Application: The antibody may be used in various immunochemical techniques including Immunoblotting (70 kDa) and ELISA.
Biochem Physiol Actions: P.aeruginosa is considered an opportunistic human pathogen mainly causing disease in immunocompromised patients. It is especially fatal in cystic fibrosis (CF) patients, but also presents a major problem in chronic wounds, burn wounds and infection of implanted biomaterials such as catheters.3The genome of P. aeruginosa encodes a vast arsenal of virulence factors such as, Type 3 secretion system (T3SS), type 4 pilli and several secreted proteases, lipases and phospholipases.1 The Exotoxin A ADP-ribosylation activity inhibits host elongation factor 2 (EF2), and protein synthesis.1 Due to its toxin ADP-ribosylation activity PE is considered as a selective agent for the elimination of specific cell populations resulting in the irreversible shut down of protein synthesis leading to cell death. To reduce the adverse effects of natural PE, mutated PE was used in several attempts to develop recombinant toxin-antibody or cytokines fusion fragments for therapeutic application including cancer immunotherapy.5-9